Permanent implant
Pivot Extend®
A long-term option that restores tricuspid valve coaptation, with the flexibility of transfemoral retrieval.
Explore Pivot ExtendFirst‑in‑class therapies for a changing heart.
Pivot‑TR is a flow-aligned, first-in-class transcatheter tricuspid repair spacer (TTRS) platform for tricuspid regurgitation. It restores leaflet coaptation through dynamic, self-centering support, without fixing anything to the heart.
Investigational device. Not commercially available.
About TAU MEDICAL
We develop transcatheter therapies for tricuspid regurgitation, designed for the patients current treatments leave behind, including those with massive and torrential TR.
Our mission is to deliver safe, simple, and effective therapies for structural heart disease. Our R&D centers and manufacturing facilities are in Busan and Yangsan, Korea.
About TauHow Pivot‑TR works
Transfemoral. Non‑fixated. Self‑centering.
Pivot‑TR positions a spacer obliquely across the tricuspid valve, held between the inferior vena cava and the pulmonary artery. It moves with the blood flow instead of resisting it, so support stays centered as the heart remodels.
01
Transfemoral
Minimally invasive and removable
Delivered transfemorally with standard catheter techniques. The same route allows retrieval if the patient’s condition or treatment strategy changes.
02
Non‑fixated
Anchored without tissue penetration
A spiral anchor in the IVC and a non-fixated pulmonary artery anchor secure the device without sutures or clips, preventing migration along the flow axis.
03
Self‑centering
Adapts as the heart changes
Oblique, flow-guided positioning lets the spacer re-center dynamically, maintaining coaptation through natural remodeling and geometric change.
One platform, permanent or temporary.
Physicians can match therapy to patient condition and long-term treatment goals, including for patients once considered too high‑risk for intervention.
Compare the two devices →
Temporary implant
Pivot Bridge®
Stabilizes frail or high‑risk patients and improves valve function, serving as a bridge and diagnostic tool for future therapies.
Explore Pivot BridgeThe clinical need
An underserved and growing population.
Tricuspid regurgitation is usually managed with medication that relieves symptoms without correcting the valve. Surgery carries significant risk and is often unsuitable for elderly or high‑risk patients.
Transcatheter treatments are being introduced, though many patients, often the most in need, are still being left out.
Understand the clinical need4.7M
Patients in Europe
with TR requiring treatment
2.5M
Patients in the U.S.
with TR requiring treatment
<10k
Surgeries per year
performed in each region
>30%
One-year mortality
in severe TR, reaching about 50% at three years
Adobe Stock preview · not licensed With the heart, not against it.
By working with the heart’s natural rhythm, Pivot‑TR optimizes coaptation without compromising the heart’s anatomical integrity, restoring valve function gently and physiologically.
See the clinical evidenceClinical progress
Publication libraryAll news- Company news Tau Medical selected for the MedTech Innovator 2026 Accelerator cohort May 2026
- Publication First-in-human experience with Pivot Bridge published in Catheterization and Cardiovascular Interventions 2026
- Publication Compassionate use of Pivot Extend in torrential TR reported in EuroIntervention Feb 2026
- Clinical study SPACER early feasibility study of Pivot Extend begins in Australia Nov 2025